"When a patient fails to take their medicine as prescribed, the consequences don't only affect them, they also put a strain on the entire healthcare system. Low medicine adherence is a complex problem that requires a multidimensional solution,"…
“We delivered our highest ever six-month normalised EBITDA in H2 2024 growing 17% over H1 2024 and building momentum for sustainable growth. Manufacturing revenue grew by 25% led by finished dose form revenue up by 33% with Commercial Pharmaceuticals…
"It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we're building Novo Nordisk's ability to serve millions more people living with serious chronic diseases in the…
“Most healthcare bodies and practitioners agree that lifestyle change is a cornerstone in effectively managing chronic disease, however sustaining these behaviours can be challenging for patients, often leading to suboptimal health outcomes,”…
"We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments. More patients benefit from our innovative treatments, and the agreement to acquire the three…
“Since 2019, YES has placed more than 139 402 youth in jobs within high growth sectors such as retail, tourism, manufacturing, automotive, SME, green economy and IT. With 53% of these youth coming from grant recipient households, we immediately…
"We are pleased to announce that we are further extending our support to Ukrainian victims of the present-day conflict with much needed pharmaceutical products and we are in the process of despatching additional supplies of Fraxiparine (for…
“Great progress has been made in delivering on our ambitious strategy to lay the foundation for strong growth. We have successfully completed the necessary steps to reach the commercialisation stage for the manufacture of mRNA platform products…
“Through our rigorous research and development process, we aim to bring innovative treatments to market that can significantly improve the quality of life for patients in Africa. By leveraging the expertise of our diverse team and forging strategic…
“The acquisition represents an attractive opportunity for Aspen to take a major step in our stated strategic objective of increasing our presence in China. Sandoz’s product portfolio, pipeline, well-established infrastructure, and experienced…
“Cabotegravir LA for PrEP has the potential to change the trajectory of HIV. The signing of sublicence agreements with three generic partners is an incredibly important milestone towards enabling broad access to this medicine in countries where…
Healthcare Biz is a New Africa Busines News Services (NABNS) publication launched in 2023 to focus focusing on the medical fraternity developments, pharmaceticals, medical and phamaceutical research, human wellness as well as medical advice and for those who seek to learn more about the healthcare sector and its developments.
Subscribe to our weekly newsletter to get the latest banking, insurance and economic news in SA.
Healthcare Biz proudly displays the "FAIR" stamp of the Press Council of South Africa, indicating our commitment to adhere to the Code of Ethics for Print and online media which prescribes that our reportage is truthful, accurate and fair. Should you wish to lodge a complaint about our news coverage, please lodge a complaint on the Press Council's website, www.presscouncil.org.za or email the complaint to enquiries@ombudsman.org.za. Contact the Press Council on 011 4843612.
© Healthcare Biz 2008-2024
